Episode Details

Cannabis and psychedelics continue to gain momentum as investors position for what could be a transformative period for both industries. In this episode of Trade To Black, hosts Shadd Dales and Anthony Varrell welcome AdvisorShares MSOS ETF Managing Director Dan Ahrens to discuss cannabis stock inflows, recent market activity, uplisting speculation, the upcoming DEA Administrative Law Judge hearing, and the growing interest surrounding psychedelic medicine. Plus we'll discuss Compass Pathways (NASDAQ: CMPS), the FDA’s rolling review process, recent executive actions supporting psychedelic research, and whether institutional investors are showing greater interest in cannabis or psychedelics.In the second half of the show, Dr. Paul Shields, Chief Medical Officer at Vantage, joins The Vantage Standard segment to discuss one of the biggest challenges facing cannabinoid medicine today: why physicians remain hesitant to prescribe CBD. If you’re following cannabis stocks, psychedelic medicine, federal reform, healthcare policy, or emerging pharmaceutical cannabinoids, this is a conversation you won’t want to miss.#CannabisStocks #MSOS #Psychedelics #CompassPathways #CBD #THC #CannabisNews #CannabisInvesting #TradeToBlack #ShaddDalesWant to see more Cannabis Reform?🎬    • Cannabis Stocks Arrive On Robinhood | TDR ...  🎬    • Why Virginia’s Governor Really Vetoed Cann...  🎬    • IRS Tax Guidance Could Boost Cannabis Prof...  🎬    • The Most Important Cannabis Hearing Yet | ...  Want to stay updated on Cannabis, Small Cap, AI, and Crypto?Subscribe to our Daily Baked newsletter:https://newsletter.thedalesreport.com...Find us on social media and podcast platforms:✅ Facebook:   / thedalesreport  ✅ Twitter:   / thedalesreport  ✅ Instagram:

Listen Now